Immune Design Corp. (NASDAQ:IMDZ) shares saw strong trading volume on Wednesday . 492,869 shares changed hands during mid-day trading, an increase of 264% from the previous session’s volume of 135,325 shares.The stock last traded at $7.26 and had previously closed at $6.88.

A number of analysts recently commented on the stock. Zacks Investment Research cut shares of Immune Design Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. Leerink Swann reiterated a “buy” rating on shares of Immune Design Corp. in a research note on Friday, June 10th. Jefferies Group restated a “buy” rating and set a $20.00 price objective on shares of Immune Design Corp. in a research note on Sunday, May 29th. Wells Fargo & Co. restated a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Finally, Cowen and Company restated a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $24.00.

The firm’s market capitalization is $146.31 million. The company’s 50 day moving average is $9.14 and its 200 day moving average is $11.60.

Immune Design Corp. (NASDAQ:IMDZ) last released its earnings results on Tuesday, May 10th. The company reported ($0.61) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.01. On average, equities analysts predict that Immune Design Corp. will post ($2.70) earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in IMDZ. Oxford Asset Management purchased a new stake in Immune Design Corp. during the fourth quarter worth $1,166,000. Jennison Associates raised its stake in Immune Design Corp. by 0.6% in the third quarter. Jennison Associates now owns 202,683 shares of the company’s stock worth $2,473,000 after buying an additional 1,224 shares during the last quarter. Finally, Jennison Associates LLC raised its stake in Immune Design Corp. by 0.4% in the fourth quarter. Jennison Associates LLC now owns 203,452 shares of the company’s stock worth $4,085,000 after buying an additional 769 shares during the last quarter.

Immune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms, ZVex and GLAAS, which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.